Chorea Market Research Report - Global Forecast till 2030

Chorea Market Research Information: by Type (Huntington‚Äôs disease, Sydenham‚Äôs chorea, Drug-induced chorea), Treatment (Medical Care, Surgical Care), Distribution Channel (Hospitals, Diagnostic Centers, Drug Stores, Pharmacies) ‚Äď forecast till 2030

ID: MRFR/HC/3782-HCR | 85 Pages | Published By Rahul Gotadki on March 2023         

Chorea Market Speak to Analyst Request a Free Sample

Chorea Market Overview


The Chorea Market is expected to reach USD 2,458.5 Million by 2030 at 12.4% CAGR during the forecast period 2022-2030. Chorea is otherwise known as motion disorder, which gives unpredictable, involuntary and irregular muscle movements. The growing awareness regarding its symptoms among the population is predicted to enhance the treatment of market and its growth rate. This is a disorder that can make a person look restless or fidgety. The rising initiative's activities by major healthcare organizations and governments are predicted to support the growth of the market in the forecast period. The growing concern and awareness regarding various muscles disorder provide the treatment for market a profitable growth. The rising commonness of Huntington's disease leads to a rise in the patient pool suffering from the chorea disorder; as a result, the demand for chorea treatment is predicted to rise. The chorea market gives details of market share, new development and product pipeline analysis, the impact of domestic and local market players, changes in market regulation, analyzing opportunities in terms of emerging revenue pockets, product approvals, product launch, strategic decision, technological innovations and expansion in the market.  


Covid-19 analysis


The sudden outbreak of the Nobel virus Covid-19 led to the implementation of lockdowns and shutdowns by governments worldwide, which directly affected the chorea market by breakage in import and export activities of the market. COVID-19 can affect the global economy in three main ways: by directly hampering production and demand, creating breakage in supply chain and market, and impacting firms and financial markets financially. The analysts monitor the global situation and explain that the market will generate profitable prospects for the producers post COVID-19 crisis. 


Chief Factors Existing In The Market 



  • Key Market Drivers


The involvement of major market players is predicted to provide higher market growth for a cure for the chorea treatment market. The population of patients is growing high in numbers and the quality of spreading diseases widely across the world. Increasing demand for advanced products, such as gene therapy and stem cell therapy, is responsible for the market growth and enhances the chorea market value. The increase in chorea disease commonness is considered to be the major driving force for market size growth in the coming years. 



  • Market Challenges


This disease is exceptionally rare, so more data and knowledge are required to cure this dangerous disease. As there is a lack of knowledge, there is a lack of awareness about how this disease is being treated. 



  • Market opportunities


The increasing use of chorea treatment in hospitals, clinics and other industries is driving the growth of the Chorea Treatment market across the globe, and it can be the greatest opportunity that provides scope to the chorea market to grow. More number of hospitals and clinics means more contribution to the economy, which is a perk for the market.



  • Market Restraints


The lack of skilled persons in manufacturing effective drugs is slightly hampering the chorea market's growth. The sudden and rapid changes in the economic strategies negatively impact the development of the chorea market share. The most challenging thing for the market development is the alternative method which is available at a lower cost. Less knowledge about generic erosion is also a factor that hampers the demand of the market.


Cumulative Evaluation Of The Market 


Chorea is an abnormal involuntary movement categorized by brief, unpredictable, abrupt, irregular, non-stereotyped movements. Chorea may worsen with anxiety and subsides during sleep and voluntary movements. The major causes of Chorea include the use of pregnancy, oral contraceptives, autoimmune disorders, paraneoplastic syndromes, hyperglycemia, hyperthyroidism, and hypoparathyroidism. In 2016 according to the Neurodegenerative Disease Management journal, the commonness of Chorea was lower in Asian populations as compared to Western Europe, Australia, and North America.


Market Segmentation


The global chorea market is divided on the basis of type, treatment, and distribution channels.


Under this type, the chorea market is classified as Huntington's disease, Rheumatic (Sydenham's Chorea), and Drug-induced Chorea.


Under the basis of the treatment, the market is classified as medical care and surgical care. The medical care is further divided into neuroleptics, dopamine-depleting agents, GABAergic drugs, coenzyme Q10, intravenous immunoglobulin, and plasmapheresis. The sub-divisions neuroleptic includes typical neuroleptics and atypical neuroleptics. The surgical care is further divided into deep brain stimulation and cell transplantation.


Under the basis of the distribution channel, the market is segmented into hospitals, clinics, diagnostic centers, drug stores, pharmacies, and others. This gives a short representation of the Chorea Market outlook.


Under the basis of symptoms, the chorea treatment market is segmented into involuntary muscle movements, milkmaid's grip, speech problems, and seizures.


Under the basis of end-users, the chorea treatment market is segmented into clinics, hospitals, ambulatory surgical centers and others.


Regional Analysis


The chorea market forecast is dominated by America owing to the increasing awareness among the population and high healthcare expenditure. In 2015 according to the Centers for Disease Control and Prevention, the total health expenditure in the U.S. was reported to be USD 3.2 trillion, and hospital care was considered for a share of 32.3%.


Europe has the second rank in the chorea market. It is expected that the support provided by the government bodies for research & development and improvement in the repaying policies in healthcare is likely to operate the market of the Europe region.


The Asia Pacific is the fastest growing chorea market owing to developing healthcare technology and a huge patient pool. Healthcare expenditure is also improving in various countries of Asia Pacific. In the years 2015-2016, according to the Australian Institute of Health and Welfare, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014-2015.


The Middle East & Africa has the lowest market due to poor medical provisions and lack of technical knowledge.


Competitive Intensity Within The Industry


According to Chorea market analysis, it has a competitive landscape that provides details by a competitor. The details that included are company financials, company overview, revenue generated, market potential, new market initiatives, investment in research and development, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above information is only related to the companies' focus on the chorea treatment market.


The major players covered in the chorea treatment market are Medtronic plc., Boston Scientific Corporation, ALEVA NEUROTHERAPEUTICS SA, Pfizer Inc., GlaxoSmithKline plc., Bausch Health Companies Inc., Teva Pharmaceutical Industries Ltd., LivaNova, PLC, H. Lundbeck A/S, Ipsen, Alnylam Pharmaceuticals Inc., RespireRx Pharmaceuticals Inc., Vertex Pharmaceuticals, Inc., Prana Biotechnology Ltd., and SOM Innovation Biotech, S.A. among other domestic and global players. 


Recent Market Developments 



  • Spark Therapeutics, Inc. formed a partnership with NeuExcell Therapeutics Inc to develop gene therapy for treating chorea patients.

  • China's national medical products association has approved Austedo, a drug expected to treat Chorea in association with H.D. by Teva pharmaceutical industries LTD. The company is expanding its patient base and revenue by geographical expansion.

  • The company Voyager Therapeutics, the gene therapy company, has now appointed AI Sandrock, the reputed researcher who spent almost half of his career overseeing the clinical development activities at Biogen as CEO.


Report Overview 


This report includes the market overview, covid-19 analysis and how it affects the market, the key drivers, the market opportunities, the key drivers, the challenges that the market face, the market restraints, the market segmentation, the regional analysis, chorea market trends, the competitive landscape, report overview and recent development of the market.


Key Industrial Segments 


On the basis of product type



  • Medication¬†

  • Surgery therapy


On the basis of the end-user application



  • Hospitals¬†

  • Clinics

  • Others


On the basis of treatment 



  • Medical care

  • Surgical care


On the basis of end-user or application



  • Clinics¬†

  • Hospitals

  • Ambulatory surgical centers¬†

  • Others.


On the basis of regions



  • North America

  • Europe¬†

  • Asia Pacific

  • South America

  • The Middle East and Africa



Speak to Analyst Ask for Customization